CTLA4 and lymphoma: In patients with CTLA-4 deficiency, surveillance for the risk of lymphomas is essential, and treatment of autoimmunity and lymphoproliferation comprehends the use of sirolimus and the biologic agent abatacept, a fusion molecule containing the extracellular domain of CTLA-4 [85].